UNC-Chapel Hill Chancellor Emeritus James Moeser talks with Shelley Earp, MD, director of the UNC Lineberger Comprehensive Cancer Center, about the creation and development of the cancer center. This discussion is the third in a series based on the book "Good to Great" by Jim Collins.
UNC scientists report that in early stage, asymptomatic non-small cell lung cancer, early brain recurrences are potentially detectable prior to surgery and recommend that physicians consider including a routine pre-operative staging brain MRI. In addition, patients whose tumors are determined to be higher risk based on the findings at surgery, should consider post-operative MRI to offer early treatment of unrecognized metastasis.
Grant from the Centers for Disease Control focuses on younger breast cancer patients
Dr. Nicholas Shaheen, professor in the UNC School of Medicine, adjunct professor in the UNC Gillings School of Global Public Health and director of the UNC Center for Esophageal Diseases and Swallowing, will co-direct Barrett’s Esophagus Translational Research Network (BETRNet) projects.
Carol Shores, MD, PhD, FACS, has been interested in the link between viruses and cancer for over 20 years, after working on virus- associated cancers as a pre-doctoral fellow in the UNC Department of Biochemistry and Biophysics. Oropharyngeal cancers, like cervical cancer, are associated with human papilloma viruses and endemic Burkitt lymphoma, a childhood cancer in sub-Saharan Africa, is associated with Epstein-Barr virus.
Jian Jin, PhD, an associate professor and director of medicinal chemistry in the Center for Integrative Chemical Biology and Drug Discovery at UNC-Chapel Hill, is featured in endeavors magazine.
CHAPEL HILL, N.C. - Patients who have high-risk non-melanoma skin carcinomas of the head and neck may benefit from concomitant radiotherapy and chemotherapy, according to a UNC-led study. Their study is the first to report on multiple patients with these skin carcinomas treated simultaneously with radio-and chemotherapy.
Noel Brewer, a professor of public health at UNC who has also studied HPV vaccine use, said the public controversy has been less harmful than the fact that many doctors simply don’t know or choose not to recommend it, or that many parents have insurance plans that don’t cover the vaccine or charge large co-pays for it.
Keith Amos, MD, quoted in The Huffington Post
Chapel Hill, NC – G-Zero Therapeutics, an RTP company started in 2008 based on technologies from the University of North Carolina at Chapel Hill, has been awarded a $3 million Phase II Small Business Innovation Research Grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.